A Phase I Study of VEGF [Vascular endothelial growth factor] Trap [aflibercept] (NSC 724770, IND 100137) in Children With Refractory Solid Tumors.

Trial Profile

A Phase I Study of VEGF [Vascular endothelial growth factor] Trap [aflibercept] (NSC 724770, IND 100137) in Children With Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 Jul 2012 Actual end date changed from Aug 2011 to Feb 2010 as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Actual end date changed from Feb 2010 to Aug 2011 as reported by ClinicalTrials.gov.
    • 15 Dec 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top